Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-10-04 pm EDT
233.02 USD   +1.12%
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act”

08/12/2022 | 06:03pm EDT
Statement on Drug Pricing Provisions Included in "Inflation Reduction Act"

Amgen strongly opposes the drug pricing provisions in the "Inflation Reduction Act" passed by Congress. Amgen has long supported proposals that help patients get the medicines they need, while also preserving incentives for biopharmaceutical innovation. As passed, this bill misses the mark on both fronts.

First, the vast majority of Medicare prescription drug savings from this legislation are diverted to other priorities, leaving the majority of seniors without any guarantee of seeing lower costs at the pharmacy counter. Second, government price setting within Medicare will have a chilling effect on innovation at precisely the time when our nation needs more new medicines to treat an aging population.

We urge the Administration and Congress to refocus their efforts on sensible policy solutions like capping patients' out-of-pocket expenses, lowering deductibles, and ensuring that the rebates given to insurance companies and middlemen by companies like Amgen are passed on to patients when they purchase their medicines.

Disclaimer

Amgen Inc. published this content on 12 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2022 22:02:06 UTC.


© Publicnow 2022
All news about AMGEN INC.
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/21EU approves AstraZeneca-Amgen treatment for severe asthma
RE
09/19Novartis' Biosimilar for Osteoporosis Drug Xgeva Matches Reference Therapy in Safety, E..
MT
09/16Amgen : Is Ready to Meet Growing Demand for Innovative Medicines, Says Bradway in Bloomber..
PU
09/15Consumer group says drugmakers abuse U.S. patent system to keep prices high
RE
09/15Transcript : Amgen Inc. Presents at BofA Securities Global Healthcare Confere..
CI
09/13Asthma Peak Week : What You Need to Know About Indoor Air Pollution
PU
09/13Transcript : Amgen Inc. Presents at Morgan Stanley 20th Annual Global Healthc..
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 145 M - -
Net income 2022 6 293 M - -
Net Debt 2022 27 027 M - -
P/E ratio 2022 19,8x
Yield 2022 3,33%
Capitalization 125 B 125 B -
EV / Sales 2022 5,80x
EV / Sales 2023 5,52x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 233,02 $
Average target price 249,81 $
Spread / Average Target 7,21%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.3.58%123 269
JOHNSON & JOHNSON-3.19%429 082
ELI LILLY AND COMPANY16.41%305 529
ROCHE HOLDING AG-15.04%267 122
PFIZER, INC.-24.71%247 729
ABBVIE INC.2.16%244 563